FDA clears Phase 2 trial of oral SPG601 in men with fragile X
The FDA has approved a Phase 2 trial to test SPG601, an oral treatment candidate, in men with fragile X syndrome.| Fragile X News Today
Read about the characteristic symptoms of fragile X syndrome, which range from developmental and behavioral problems to physical features.| Fragile X News Today
Category archive page for News.| Fragile X News Today
The FDA has approved a Phase 2 trial to test SPG601, an oral treatment candidate, in men with fragile X syndrome.| Fragile X News Today
The LivJoy Foundation is funding a four-year postdoctoral fellowship for a scientist at USC who will study fragile X syndrome in females.| Fragile X News Today
Learn about fragile X syndrome, the most common cause of inherited intellectual disability and autism spectrum disorders.| Fragile X News Today
